[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dose-finding-study\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dose-finding-study":79},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100621771","phase-4-minimal-effective-volume-90-for-double-injection-costoclavicular-block-100621771",false,"NCT07374952","Minimal Effective Volume 90% for Double-injection Costoclavicular Block","Minimum Effective Volume of Lidocaine for Double-Injection Ultrasound-Guided Costoclavicular Block","Inclusion Criteria:\n\n* Age between 18 and 70 years\n* American Society of Anesthesiologists classification 1-3\n* Body mass index between 20 and 30\n\nExclusion Criteria:\n\n* Adults who are unable to give their own consent\n* Pre-existing neuropathy (assessed by history and physical examination)\n* Coagulopathy (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. platelets≤ 100, International Normalized Ratio≥ 1.4 or partial prothrombin time ≥ 50)\n* Renal failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. creatinine≥ 100)\n* Hepatic failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. transaminases≥ 100)\n* Allergy to LA\n* Pregnancy\n* Prior surgery in the infraclavicular region\n* Chronic pain syndromes requiring opioid intake at home","ALL","18 Years","70 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","In 2020, a trial demonstrated that a 2-injection technique constitutes the optimal method for the costoclavicular block.\n\nThis study aims to determine the minimum amount of medication required to achieve a successful double-injection costoclavicular nerve.\n\nBlock dose assignment will be done using an up-and-down sequential method, called the Biased Coin Design (BCD).\n\nThe double-injection technique for US-guided costoclavicular block consists in depositing two thirds of the LA volume in the deep compartment (to anesthetize the posterior and medial cords), and one third of the injectate in the superficial compartment (to anesthetize the lateral cord).\n\nThe ED90 will be calculated using isotonic regression with a 95% confidence interval derived by bootstrapping.",[27,28,29,30,31],"Brachial Plexus Blocks","Lidocaine","Nerve Block","Dose Finding Study","Costoclavicular Block",[33,34,35,36,37],"costoclavicular block","double injection technique","dose finding","nerve block","lidocaine","NOT_YET_RECRUITING","2026-02-18",{"date":41,"type":42},"2026-02-20","ACTUAL",{"date":44,"type":21},"2026-02-01",{"date":46,"type":21},"2026-12-31",{"name":48,"class":49},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":57,"minAge":17,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100418584","phase-4-dexmedetomidine-for-intraoperative-shivering-in-scheduled-elective-cesarean-delivery-100418584","NCT04730609","Dexmedetomidine for Intraoperative Shivering in Scheduled Elective Cesarean Delivery","Dexmedetomidine for Treatment of Shivering During Scheduled Elective Cesarean Delivery: Determining the Optimal Dose","Inclusion Criteria:\n\n* Women presenting for planned cesarean delivery.\n* American Society of Anesthesiology Physical Classification Status 2 or 3; without major medical co-morbidities.\n* Singleton gestation in the 3rd trimester (28-42 weeks gestation).\n* Spinal anesthesia technique Women presenting for planned cesarean delivery.\n* American Society of Anesthesiology Physical Classification Status 2 or 3; without major medical co-morbidities.\n* Singleton gestation in the 3rd trimester (28-42 weeks gestation).\n* Spinal anesthesia technique.\n\nExclusion Criteria:\n\n* Any contraindication to spinal anesthesia technique.\n* Allergy or intolerance to dexmedetomidine or clonidine.\n* Oral temperature \\\u003C 36° Celsius prior to procedure.\n* Unable to give personal consent.\n* PPROM or concern for infection (e.g., chorioamnionitis).\n* Conversion to General Anesthesia prior to randomization.\n* Sedative medications (e.g., fentanyl, midazolam, ketamine, nitrous oxide) administered prior to randomization.","FEMALE",{"count":59,"type":21},40,[24],"The purpose of this study is to determine the optimum dose of Dexmedetomidine to stop shivering in 90% of patients who experience shivering during scheduled elective cesarean deliveries.",[63,30],"Shivering",[63,65,66,67],"Cesarean Delivery","Dexmedetomidine","Dosing","RECRUITING","2025-09-05",{"date":71,"type":42},"2025-09-11",{"date":73,"type":42},"2021-09-21",{"date":75,"type":21},"2026-08",{"name":77,"class":49},"Mayo Clinic",1,"Dose-Finding Study"]